Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: UL stock price vs BIO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BIO's multiple
Needs BIO P/E.
Implied fair value · at UL's multiple
Needs UL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
USD conversion input: 1 EUR = 1.116500 USD. FX date unavailable.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
UNILEVER PLC · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
BIO-RAD LABORATORIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
UL vs PG
COLGATE PALMOLIVE CO
UL vs CL
JOHNSON & JOHNSON
UL vs JNJ
KIMBERLY CLARK CORP
UL vs KMB
CHURCH & DWIGHT CO INC /DE/
UL vs CHD
DANAHER CORP /DE/
UL vs DHR
ILLUMINA, INC.
UL vs ILMN
AGILENT TECHNOLOGIES, INC.
UL vs A
BIO-TECHNE Corp
UL vs TECH
BRUKER CORP
UL vs BRKR
Azenta, Inc.
UL vs AZTA
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe UL can reaccelerate growth and sustain its current margins while reducing leverage, then hold rather than add aggressively because BIO-based P/E model shows 8.3% downside and the valuation is not clearly cheap on a mixed fundamentals picture.
On the provided P/E framework, UL's implied price of $58.12 is below the current price of $63.41, indicating an 8.3% downside to BIO-based valuation. UL also sits within its historical band but closer to the upper half than the DCF range, which implies the market is pricing in more than the discounted cash flow view would support.
Supporting Metrics
